Lisata Therapeutics, Inc. (LON:0HS8)

London flag London · Delayed Price · Currency is GBP · Price in USD
2.590
+0.087 (3.48%)
At close: Feb 13, 2025
-0.77%
Market Cap 16.93M
Revenue (ttm) n/a
Net Income (ttm) -15.47M
Shares Out n/a
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 863
Average Volume 1,064
Open 2.590
Previous Close 2.503
Day's Range 2.590 - 2.590
52-Week Range 2.061 - 2.990
Beta 1.15
RSI 42.56
Earnings Date Feb 27, 2025

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ c... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 25
Stock Exchange London Stock Exchange
Ticker Symbol 0HS8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.